Phase I/II study of HP-3060 in patients with allergic rhinitis.
Phase 1
- Conditions
- Allergic rhinitis
- Registration Number
- JPRN-jRCT2080222141
- Lead Sponsor
- Hisamitsu Pharmaceutical Co., Inc.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Subjects with a disease duration of 2 years or more and a positive result for serum specific IgE antibody on quantitative assessment.
Exclusion Criteria
- Allergic rhinitis complicated by other types of rhinitis, such as infectious rhinitis, vasomotor rhinitis, or eosinophilic rhinitis
- Allergic rhinitis complicated by chronic sinusitis
- Hyposensitization therapy or nonspecific immunotherapy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method